Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: A patient-level pooled analysis

Medicine & Life Sciences

• Insulin Glargine 100%
• Thiazolidinediones 93%
• Type 2 Diabetes Mellitus 53%
• Lipids 46%
• lipoprotein cholesterol 30%
• LDL Cholesterol 21%
• HDL Cholesterol 14%
• Cholesterol 11%
• lipoprotein triglyceride 10%
• Rosiglitazone 10%
• Pioglitazone 10%
• Metformin 8%
• Nonesterified Fatty Acids 8%
• Dyslipidemias 7%
• Hypoglycemia 7%
• Weight Gain 7%
• Edema 6%
• Triglycerides 6%
• Cardiovascular Diseases 5%
• Clinical Studies 5%
• Health Care Outcome Assessment 5%
• Therapeutics 3%
• Population 3%